Professor Bernd Wollscheid: Strong engagement in HUPO and outstanding research results
Professor Bernd Wollscheid elected council member & member of the executive committee of the Human Proteome Organization (HUPO). Currently, he was substantially involved in an important research success that promises hope for patients with a severe metabolic disease.
Professor Bernd Wollscheid, responsible scientist of the Molecular Health Research Group of the Institute of Translational Medicine, was elected as a council member & member of the executive committee of the Human Proteome Organization (HUPO). The Human Proteome Organization (HUPO) is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training. Since the first World Congress HUPO in 2001, the Congress has become a premier forum for discussions and contributions to "translate the code of life”.
A main pillar is the Human Proteome Project (HPP) - which is an international project organized by HUPO that aims to revolutionize our understanding of the human proteome via a coordinated effort by many research laboratories around the world. It is designed to map the entire human proteome in a systematic effort using currently available and emerging techniques. Completion of this project will enhance understanding of human biology at the cellular level and lay a foundation for development of diagnostic, prognostic, therapeutic, and preventive medical applications."
Find out more about the external pageHuman Proteome Organization (HUPO)
Latest research success
Currently, Bernd Wollscheid was substantially involved in an important research success that promises hope for patients with a severe metabolic disease.
New research offers potential benefits for those affected by the hereditary metabolic disease methylmalonic aciduria. By combining the results of multiple molecular analyses, scientists can better diagnose this rare and severe disease. In the future, an improved understanding of the disease might also improve treatment options.
This is the first time that MMA has been studied using a multi-omics approach (genomics, transcriptomics, proteomics, metabolomics). The work was initiated and funded by the ETH domain strategic focus area Personalized Health and Related Technologies (PHRT) and involved researchers from the University Children’s Hospital Zurich, ETH Zurich, EPFL, the University of Zurich, and the Health 2030 Genome Center in Geneva. The molecular analysis was carried out at PHRT’s Swiss Multi-Omics Center (SMOC) in Zurich.
Read more